PA
ABUS icon

Perceptive Advisors’s Arbutus Biopharma ABUS Stock Holding History

Perceptive Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-100,000
Closed -$2.15M – 119
2014
Q1 		$2.15M Buy
+100,000
New +$1.8M 0.23% 65

Other funds holding ABUS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Perceptive Advisors's ABUS Position: Q4 2013 in Review

Perceptive Advisors sold out of Arbutus Biopharma (ABUS) in Q4 2013, closing a stake of 159,309 shares — an estimated $1.11M sold.

Perceptive Advisors first reported a position in ABUS in Q2 2013 and held it in 2 quarters. The position peaked at $1.24M in Q2 2013. 24 funds tracked by Wall St. Rank hold ABUS as of Q4 2013.

  • Perceptive Advisors reported no remaining Arbutus Biopharma position as of Q4 2013 after selling out during the quarter.
  • Perceptive Advisors sold 159,309 Arbutus Biopharma shares in Q4 2013, an estimated $1.11M.
  • Perceptive Advisors first reported a position in Arbutus Biopharma in Q2 2013 and held it in 2 quarters.
  • Perceptive Advisors's Arbutus Biopharma position peaked at $1.24M in Q2 2013.
  • 24 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2013.

Based on Perceptive Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.